3 Biotechs Investors Should Put on Their Watchlist

Investor

Investor

Three companies remain favorites, and all are rated Buy at Jefferies.

During 2015 and last year as the brutal presidential campaign played out, the health care sector, and especially the drugmakers, became one of the favorite whipping boys for the candidates, who cited high drug prices as a major issue. While lower pricing is still wanted by all, the harsh rhetoric has died down some, and the sector took off with the rest of the market and now sits at all-time highs as well.

MORE ON THIS TOPIC